Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

医学 临床终点 热疗 软组织肉瘤 异环磷酰胺 化疗 依托泊苷 肉瘤 内科学 外科 阿霉素 肿瘤科 随机对照试验 软组织 病理
作者
Rolf D. Issels,Lars H. Lindner,Jaap Verweij,Peter Wust,Peter Reichardt,Baard‐Christian Schem,Sultan Abdel-Rahman,Soeren Daugaard,Christoph Salat,Clemens‐Martin Wendtner,Željko Vujašković,Rüdiger Wessalowski,Karl‐Walter Jauch,Hans Roland Dürr,Ferdinand Ploner,Andrea Baur‐Melnyk,Ulrich Mansmann,Wolfgang Hiddemann,Jean‐Yves Blay,Peter Hohenberger
出处
期刊:Lancet Oncology [Elsevier]
卷期号:11 (6): 561-570 被引量:612
标识
DOI:10.1016/s1470-2045(10)70071-1
摘要

Summary

Background

The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.

Methods

Patients were recruited to the trial between July 21, 1997, and November 30, 2006, at nine centres in Europe and North America. Patients with localised high-risk STS (≥5 cm, Fédération Nationale des Centres de Lutte Contre le Cancer [FNCLCC] grade 2 or 3, deep to the fascia) were randomly assigned to receive either neo-adjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin (EIA) alone, or combined with regional hyperthermia (EIA plus regional hyperthermia) in addition to local therapy. Local progression-free survival (LPFS) was the primary endpoint. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT 00003052.

Findings

341 patients were enrolled, with 169 randomly assigned to EIA plus regional hyperthermia and 172 to EIA alone. All patients were included in the analysis of the primary endpoint, and 332 patients who received at least one cycle of chemotherapy were included in the safety analysis. After a median follow-up of 34 months (IQR 20–67), 132 patients had local progression (56 EIA plus regional hyperthermia vs 76 EIA). Patients were more likely to experience local progression or death in the EIA-alone group compared with the EIA plus regional hyperthermia group (relative hazard [RH] 0·58, 95% CI 0·41–0·83; p=0·003), with an absolute difference in LPFS at 2 years of 15% (95% CI 6–26; 76% EIA plus regional hyperthermia vs 61% EIA). For disease-free survival the relative hazard was 0·70 (95% CI 0·54–0·92, p=0·011) for EIA plus regional hyperthermia compared with EIA alone. The treatment response rate in the group that received regional hyperthermia was 28·8%, compared with 12·7% in the group who received chemotherapy alone (p=0·002). In a pre-specified per-protocol analysis of patients who completed EIA plus regional hyperthermia induction therapy compared with those who completed EIA alone, overall survival was better in the combined therapy group (HR 0·66, 95% CI 0·45–0·98, p=0·038). Leucopenia (grade 3 or 4) was more frequent in the EIA plus regional hyperthermia group compared with the EIA-alone group (128 of 165 vs 106 of 167, p=0·005). Hyperthermia-related adverse events were pain, bolus pressure, and skin burn, which were mild to moderate in 66 (40·5%), 43 (26·4%), and 29 patients (17·8%), and severe in seven (4·3%), eight (4·9%), and one patient (0·6%), respectively. Two deaths were attributable to treatment in the combined treatment group, and one death was attributable to treatment in the EIA-alone group.

Interpretation

To our knowledge, this is the first randomised phase 3 trial to show that regional hyperthermia increases the benefit of chemotherapy. Adding regional hyperthermia to chemotherapy is a new effective treatment strategy for patients with high-risk STS, including STS with an abdominal or retroperitoneal location.

Funding

Deutsche Krebshilfe, Helmholtz Association (HGF), European Organisation of Research and Treatment of Cancer (EORTC), European Society for Hyperthermic Oncology (ESHO), and US National Institute of Health (NIH).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Vera61发布了新的文献求助10
1秒前
金扇扇完成签到,获得积分10
2秒前
打打应助Singularity采纳,获得10
2秒前
qzliyulin发布了新的文献求助10
2秒前
JUDGEsir完成签到,获得积分10
3秒前
勤恳的纸飞机完成签到,获得积分10
3秒前
研友_nPKAEL完成签到,获得积分10
4秒前
4秒前
zz完成签到,获得积分10
5秒前
平凡之路完成签到,获得积分10
6秒前
998877剑指完成签到,获得积分10
6秒前
7秒前
大模型应助金扇扇采纳,获得10
7秒前
8秒前
10秒前
海洋完成签到,获得积分10
10秒前
11秒前
Owen应助zzw采纳,获得10
11秒前
Patrick0614发布了新的文献求助10
12秒前
bin发布了新的文献求助20
12秒前
飞飞完成签到 ,获得积分10
12秒前
田様应助尊敬薯片采纳,获得10
13秒前
13秒前
13秒前
小贝发布了新的文献求助50
14秒前
夕阳殆晖发布了新的文献求助10
14秒前
15秒前
lirongcas发布了新的文献求助10
15秒前
脏脏鲤完成签到 ,获得积分10
16秒前
共享精神应助Vera61采纳,获得30
16秒前
18秒前
一顿鸡米花完成签到,获得积分10
18秒前
从容芮应助默默焱采纳,获得30
18秒前
20秒前
逃之夭夭发布了新的文献求助30
20秒前
21秒前
22秒前
爆米花应助L同学采纳,获得10
23秒前
23秒前
23秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3229144
求助须知:如何正确求助?哪些是违规求助? 2876975
关于积分的说明 8197101
捐赠科研通 2544315
什么是DOI,文献DOI怎么找? 1374291
科研通“疑难数据库(出版商)”最低求助积分说明 646923
邀请新用户注册赠送积分活动 621720